Rifampin
Rifadin, Rimactane (rifampicin)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| All forms of tuberculosis | Adults and pediatric patients | Combination therapy (multi-drug regimen) | FDA Approved |
| Asymptomatic meningococcal carriers | Adults and pediatric patients | Short-course eradication | FDA Approved |
Rifampin is one of the most important antimycobacterial agents available. It serves as a backbone of first-line tuberculosis therapy and is administered alongside isoniazid, pyrazinamide, and ethambutol during the intensive phase. For meningococcal carriage, rifampin eliminates Neisseria meningitidis from the nasopharynx but is not used to treat active meningococcal disease due to the rapid emergence of resistance.
Latent tuberculosis infection (LTBI) — 4-month rifampin monotherapy: CDC-preferred short-course regimen. Evidence quality: High (randomized trials demonstrate non-inferiority to 9-month isoniazid with superior completion rates and fewer hepatic adverse events).
Prosthetic joint infection / osteomyelitis (staphylococcal): Adjunctive to a primary antibiotic to eradicate biofilm organisms. Evidence quality: Moderate (RCTs showing improved cure rates when added to a beta-lactam or fluoroquinolone for prosthetic joint infections).
Leprosy (Hansen disease): Component of multi-drug therapy alongside dapsone and clofazimine. Evidence quality: High (WHO standard of care).
Haemophilus influenzae type b prophylaxis: Post-exposure prophylaxis for close contacts of index cases, particularly households with children under 4 years. Evidence quality: Moderate.
Cholestatic pruritus (primary biliary cholangitis): Second-line agent for refractory pruritus. Evidence quality: Moderate (small RCTs showing benefit, but hepatotoxicity risk limits use).
MRSA infections (adjunctive): Combined with a primary agent for endocarditis, osteomyelitis, and device-related infections. Evidence quality: Moderate (mixed data; a large RCT found no benefit in bacteraemia).
Dosing
Adult Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Active TB — intensive phase (daily) | 10 mg/kg once daily | 600 mg once daily | 600 mg/day | Part of 4-drug regimen (RIF + INH + PZA + EMB) for 2 months Take 1 h before or 2 h after meals |
| Active TB — continuation phase (daily) | 600 mg once daily | 600 mg once daily | 600 mg/day | Given with isoniazid for ≥4 additional months Extend if culture-positive, resistant organisms, or HIV-positive |
| Active TB — twice-weekly DOT | 600 mg twice weekly | 600 mg twice weekly | 600 mg/dose | Only under directly observed therapy (DOT) Doses >600 mg intermittently increase adverse reaction risk |
| Latent TB — 4-month rifampin monotherapy | 10 mg/kg once daily | 600 mg once daily | 600 mg/day | CDC-preferred short-course LTBI regimen Better completion rates and fewer hepatic events than 9-month INH |
| Meningococcal carrier eradication | 600 mg every 12 hours | 600 mg every 12 hours | 1200 mg/day | Duration: 2 days only Not for treatment of active meningococcal disease |
| Staphylococcal prosthetic joint infection (adjunctive) | 300–450 mg every 12 hours | 300–450 mg every 12 hours | 900 mg/day | Combined with a primary agent (e.g., fluoroquinolone, beta-lactam) Duration determined by surgical approach and clinical response |
| Leprosy — multibacillary (WHO regimen) | 600 mg once monthly | 600 mg once monthly | 600 mg/dose | Supervised, combined with dapsone + clofazimine for 12 months NHDP recommends daily rifampin for patients in the US |
Pediatric Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Active TB — daily regimen (≥1 month) | 10–20 mg/kg once daily | 10–20 mg/kg once daily | 600 mg/day | Combined with INH, PZA, EMB WHO recommends 15 mg/kg for children; AAP range 10–20 mg/kg |
| Latent TB — 4-month regimen (≥2 years) | 15–20 mg/kg once daily | 15–20 mg/kg once daily | 600 mg/day | Duration: 4 months AAP: some experts use 20–30 mg/kg for infants and toddlers |
| Meningococcal carrier — ≥1 month | 10 mg/kg every 12 hours | 10 mg/kg every 12 hours | 600 mg/dose | Duration: 2 days |
| Meningococcal carrier — neonates (<1 month) | 5 mg/kg every 12 hours | 5 mg/kg every 12 hours | 5 mg/kg/dose | Duration: 2 days |
Rifampin should be taken on an empty stomach (1 hour before or 2 hours after meals) with a full glass of water for optimal absorption. Food reduces absorption by approximately 30%. Antacids containing aluminum should not be taken within 1 hour of rifampin. IV and oral doses are equivalent (1:1 conversion).
Pharmacology
Mechanism of Action
Rifampin exerts its bactericidal effect by binding to the beta subunit of bacterial DNA-dependent RNA polymerase (RNAP), blocking the elongation of messenger RNA transcripts. This selective inhibition halts RNA synthesis in susceptible organisms while sparing mammalian RNA polymerase, which has a structurally distinct binding site. The drug is active against both intracellular and extracellular Mycobacterium tuberculosis, making it particularly effective against persisting organisms within macrophages. Rifampin is also a potent inducer of hepatic cytochrome P450 enzymes (especially CYP3A4), P-glycoprotein, and UGT enzymes, which accounts for its extensive drug interaction profile. Resistance develops rapidly through single-step mutations in the rpoB gene encoding the RNAP beta subunit, necessitating combination therapy for all therapeutic indications.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapidly absorbed; Tmax ~2 h; well absorbed orally (fasting) | Food reduces absorption by ~30%; administer on an empty stomach for consistent drug levels; peak serum concentration averages 7 mcg/mL after 600 mg dose |
| Distribution | Vd 0.64–0.66 L/kg; ~80% protein bound; penetrates CSF, lungs, liver, bone | Achieves therapeutic concentrations in most tissues including CSF, supporting use in TB meningitis and osteoarticular infections |
| Metabolism | Hepatic deacetylation to active metabolite 25-desacetyl-rifampin; auto-induction of own metabolism | Half-life shortens from ~3.35 h to 2–3 h with repeated dosing due to auto-induction; potent inducer of CYP3A4, 2C9, 2C19, 2B6, 1A2, P-gp |
| Elimination | Biliary excretion (enterohepatic circulation); up to 30% renal (half as unchanged drug) | No dose adjustment needed for renal impairment at doses ≤600 mg/day; half-life prolonged at higher doses in renal failure |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Orange-red discoloration of body fluids (urine, tears, sweat, saliva, sputum) | ~100% | Harmless pharmacological effect; intensity proportional to dose. Permanently stains soft contact lenses. |
| Transient LFT elevation (AST/ALT) | 10–20% | Mild, self-limiting elevations occur early in therapy; distinguish from clinically significant hepatotoxicity by magnitude and symptoms |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea / vomiting | 1–5% | Dose-related; taking with food may reduce symptoms but decreases absorption by ~30% |
| Abdominal pain / heartburn | 1–5% | Usually mild and self-limiting; consider taking with a small snack if severe |
| Diarrhea | 1–5% | Rule out C. difficile if persistent or bloody |
| Anorexia | 1–5% | Monitor weight in prolonged therapy; may overlap with TB disease symptoms |
| Headache | 1–5% | Generally resolves within the first weeks of therapy |
| Drowsiness / dizziness | 1–3% | Caution with driving or operating machinery, particularly during the first week |
| Rash / pruritus | 1–5% | Mild cutaneous reactions are self-limiting; discontinue if severe or progresses to blistering |
| Flu-like syndrome (intermittent dosing) | 1–5% | Fever, chills, malaise; more common with interrupted or intermittent regimens; can occur upon resumption of therapy after a drug-free interval |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Hepatotoxicity (hepatocellular, cholestatic, or mixed) | 1–3% (rifampin alone); 2.5–3% (with INH) | First 2–8 weeks, but can occur at any time | Monitor LFTs; hold rifampin if ALT >3× ULN with symptoms or >5× ULN without symptoms; specialist review before rechallenge |
| Severe cutaneous reactions (SJS, TEN, DRESS, AGEP) | Rare (<0.1%) | Days to weeks | Immediate permanent discontinuation; emergency dermatology and supportive care |
| Thrombocytopenia | Rare; higher with intermittent dosing | Weeks to months; more common with resumed/intermittent therapy | Check platelet count urgently; discontinue rifampin permanently if confirmed immune-mediated |
| Hemolytic anemia (immune-mediated) | Rare; primarily with intermittent >600 mg doses | Hours to days after resumption of intermittent dosing | Permanent discontinuation; supportive care including transfusion if needed |
| Acute renal failure (interstitial nephritis, tubular necrosis) | Rare (<0.1%) | Typically with intermittent or resumed therapy | Discontinue permanently; renal consultation; supportive care |
| Interstitial lung disease / pneumonitis | Very rare | Weeks to months | Discontinue immediately; chest imaging; may require corticosteroids |
| Anaphylaxis / systemic hypersensitivity | Very rare | Minutes to hours after dose | Emergency treatment with epinephrine; permanent discontinuation |
| Coagulopathy (vitamin K–dependent) | Uncommon | Weeks; risk increases with hepatic impairment, malnutrition | Monitor PT/INR; administer supplemental vitamin K; consider dose adjustment or discontinuation if bleeding occurs |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Hepatotoxicity (ALT >5× ULN) | ~1–2% | Rifampin monotherapy (LTBI); higher when combined with isoniazid or pyrazinamide |
| GI intolerance | ~1% | Nausea, vomiting severe enough to warrant discontinuation |
| Rash / hypersensitivity | <1% | Mild rashes can be managed with antihistamines; severe reactions require permanent discontinuation |
The risk of clinically significant hepatotoxicity from rifampin alone is relatively low (~1–2%) but increases substantially when combined with isoniazid (~2.5–3%) or pyrazinamide. Key risk factors include age over 35, pre-existing liver disease, alcohol use, and HIV co-infection. Hold all hepatotoxic TB drugs if ALT exceeds 3 times the upper limit of normal with symptoms, or 5 times ULN without symptoms. Rechallenge should be sequential, reintroducing one drug at a time, typically starting with rifampin (which has a lower hepatotoxicity risk than isoniazid or pyrazinamide).
Drug Interactions
Rifampin is the most potent known inducer of hepatic CYP450 enzymes (especially CYP3A4, but also 2C9, 2C19, 2B6, 1A2) and drug transporters (P-glycoprotein, MRP2, UGTs). Enzyme induction reaches clinical significance within approximately 1 week and persists for about 2 weeks after discontinuation. The breadth of its interaction profile is unmatched by any other antimicrobial, and a thorough medication reconciliation is essential before initiating therapy.
The interactions listed above are representative, not exhaustive. Rifampin significantly reduces the levels of dozens of drug classes including direct oral anticoagulants (DOACs), azole antifungals (itraconazole, voriconazole), calcium channel blockers, sulfonylureas, statins, thyroid hormones, and many others. A comprehensive drug interaction check is mandatory before starting rifampin. The induction effect begins within a few days, peaks at approximately 1 week, and persists for roughly 2 weeks after rifampin is stopped.
Monitoring
-
Hepatic Enzymes (ALT, AST, Bilirubin)
Baseline; then every 2–4 weeks if risk factors present
Routine Obtain baseline LFTs for all adults on TB treatment. Routine follow-up testing is recommended for patients with pre-existing liver disease, alcohol use, HIV, age >35, or concomitant hepatotoxic drugs. Hold therapy if ALT >3× ULN with symptoms or >5× ULN without symptoms. -
CBC with Platelets
Baseline; repeat if clinically indicated
Routine Baseline for all adults on TB treatment. Repeat for unexplained bruising, petechiae, or bleeding. Thrombocytopenia and hemolytic anemia are rare but serious, especially with intermittent dosing. -
Serum Creatinine / BUN
Baseline
Routine Obtain before initiating therapy. Acute renal failure is rare and typically associated with intermittent or resumed dosing. Repeat if symptoms of renal impairment develop. -
PT / INR (Coagulation)
Baseline; ongoing if on anticoagulants or at risk
Trigger-based Monitor prothrombin time in patients on warfarin (very frequent monitoring required), patients with liver disease, malnutrition, or prolonged antibiotic courses. Consider supplemental vitamin K if abnormal. -
Sputum Cultures / Susceptibility
Baseline and monthly until conversion
Routine Confirm susceptibility before starting rifampin. Repeat cultures monthly during treatment to monitor response. Persistent positive cultures at 3 months warrant review for resistance or non-adherence. -
Clinical Symptom Review
Monthly
Routine Ask specifically about jaundice, dark urine, anorexia, nausea, abdominal pain, rash, bruising, and flu-like symptoms at each visit. Patient-reported symptoms may precede laboratory abnormalities. -
Drug Interaction Review
At initiation and any medication change
Trigger-based Review all concomitant medications (including OTC and herbal products) before starting rifampin and whenever medications are added or changed during therapy. Check dose adjustments for interacting drugs.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to rifampin or any rifamycin (rifabutin, rifapentine)
- Concurrent use of ritonavir-boosted saquinavir — severe hepatocellular toxicity (FDA PI)
- Concurrent use of atazanavir, darunavir, fosamprenavir, saquinavir, or tipranavir — loss of antiviral efficacy and resistance
- Concurrent use of praziquantel — sub-therapeutic praziquantel levels (discontinue rifampin 4 weeks before praziquantel)
Relative Contraindications (Specialist Input Recommended)
- Pre-existing liver disease or active hepatitis: Use only when benefit outweighs risk under close supervision with LFT monitoring every 2–4 weeks. Dose reduction may be necessary.
- Concurrent hepatotoxic medications (isoniazid, pyrazinamide, halothane): Increased hepatotoxicity risk; dedicated monitoring plan required.
- HIV patients on antiretroviral therapy: Complex drug interactions; infectious disease and HIV specialist co-management essential; rifabutin generally preferred.
- Solid organ transplant recipients on calcineurin inhibitors: Risk of graft rejection from dramatically reduced immunosuppressant levels.
- Porphyria: Rifampin induces delta-aminolevulinic acid synthetase and may exacerbate acute porphyria.
Use with Caution
- Diabetes mellitus: Rifampin may make glycaemic control more difficult through enzyme induction effects on oral hypoglycaemics
- Patients on warfarin or DOACs: Intensive INR monitoring or alternative anticoagulation strategy
- Patients wearing soft contact lenses: Permanent staining of lenses by orange-red discoloration of tears
- Patients who cannot guarantee daily adherence: Intermittent dosing increases risk of flu syndrome, renal failure, hemolytic anemia, and thrombocytopenia
- Elderly patients: Higher risk of drug-induced hepatitis; higher incidence of polypharmacy interactions
- Pregnancy (last few weeks): May increase risk of maternal postpartum hemorrhage and neonatal bleeding; vitamin K should be administered to the neonate
Cases of fatal and non-fatal hepatotoxicity (hepatocellular, cholestatic, and mixed patterns) have been reported in patients receiving rifampin, ranging from asymptomatic enzyme elevations to fulminant liver failure. Risk is increased in patients with pre-existing liver disease and those receiving concomitant hepatotoxic agents. Monitor liver function and discontinue rifampin if signs of hepatic damage develop. When rifampin is combined with other hepatotoxic drugs, especially isoniazid, patients should be monitored closely.
Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. Discontinue rifampin immediately if signs of severe skin reactions develop.
Patient Counselling
Purpose of Therapy
Rifampin is a key antibiotic in treating tuberculosis and preventing certain bacterial infections. It works by killing bacteria that cause TB and can also clear meningococcal bacteria from the nose and throat. It is essential to complete the entire course of treatment, even if symptoms improve quickly, to prevent the development of drug-resistant bacteria.
How to Take
Take rifampin on an empty stomach with a full glass of water, either 1 hour before or 2 hours after a meal. Do not take aluminum-containing antacids within 1 hour of rifampin. If the capsule cannot be swallowed, a pharmacist can prepare a liquid suspension. Never stop taking rifampin without discussing with your healthcare provider, even if you feel better, and do not skip doses.
Sources
- Rifadin (rifampin) capsules and Rifadin IV prescribing information. Sanofi-Aventis U.S. LLC. Revised 2022. FDA Label Primary source for approved indications, dosing, contraindications, warnings, and pharmacokinetic data used throughout this monograph.
- DailyMed. Rifampin capsule — drug label information. National Library of Medicine. DailyMed Supplementary labelling source confirming adverse reactions, dosing, and interaction data for generic rifampin formulations.
- Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440–453. DOI Landmark non-inferiority RCT demonstrating 4-month rifampin has comparable efficacy with significantly fewer hepatic adverse events than 9-month isoniazid for LTBI.
- Thwaites GE, Scarborough M, Szubert A, et al. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10121):668–678. DOI Large RCT finding no overall benefit from adjunctive rifampin in S. aureus bacteraemia, informing current off-label use recommendations.
- Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351(16):1645–1654. DOI Seminal review establishing rifampin’s role in biofilm-active combination therapy for prosthetic joint infections.
- Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1–11. DOI Current CDC guidelines preferentially recommending short-course rifamycin-based LTBI regimens including 4-month rifampin.
- Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society / Centers for Disease Control and Prevention / Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147–e195. DOI Comprehensive guidelines for active TB treatment, providing dosing recommendations and regimen structures referenced in the dosing section.
- Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–952. DOI ATS consensus statement on monitoring for and managing hepatotoxicity during anti-TB treatment, informing the monitoring and side effects sections.
- Campbell EA, Korzheva N, Mustaev A, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. 2001;104(6):901–912. DOI Crystal structure study elucidating how rifampin binds bacterial RNA polymerase, foundational for understanding mechanism of action and resistance.
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Rifampin. National Institute of Diabetes and Digestive and Kidney Diseases, 2018. NCBI Comprehensive NIH resource on rifampin hepatotoxicity patterns, mechanisms, and clinical presentation informing the side effects and monitoring sections.
- Suresh AB, Rosani A, Engel K. Rifampin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. NCBI Comprehensive pharmacology review covering rifampin’s PK profile, pediatric dosing, adverse effects, and drug interactions.
- Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192–202. DOI Review of anti-TB drug hepatotoxicity incidence (2–28%), risk factors, and management, supporting discontinuation rate estimates.
- Ibrahim M, Patel N, Engel K, et al. A literature review of liver function test elevations in rifampin drug-drug interaction studies. Clin Transl Sci. 2022;15(7):1547–1560. DOI Systematic review of LFT elevations in rifampin DDI studies, particularly with ritonavir-boosted protease inhibitors, informing interaction card content.